<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031664</url>
  </required_header>
  <id_info>
    <org_study_id>Qianjin Capsule</org_study_id>
    <nct_id>NCT04031664</nct_id>
  </id_info>
  <brief_title>A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)</brief_title>
  <official_title>A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)：a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Obstetrics and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Hospital of Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety of Qianjin Capsule of
      Gynaecology combined with antibiotics for pelvic inflammatory diseases (Damp-heat Stasis and
      Qi Deficiency Syndrome) for the short-term and long-term efficacy of traditional Chinese
      medicine in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The MCCormack scale scores of 184 subjects will be assessed</measure>
    <time_frame>Change from base line on the 56 days after discontinuation</time_frame>
    <description>assessment of the 70% reduction rate after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The neutrophils of 184 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>assessment of neutrophils returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The whole blood reduced viscosity from hemorheological tests of 184 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 day of medication.</time_frame>
    <description>assessment of whole blood viscosity returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma viscosity from hemorheological tests of 184 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 day of medication.</time_frame>
    <description>assessment of the plasma viscosity returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The fibrinogen determination from hemorheological tests of 184 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 day of medication.</time_frame>
    <description>assessment of the fibrinogen determination returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The CRP of 184 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 day of medication.</time_frame>
    <description>assessment of the CRP returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The volume of liquid on B-mode of 184 subjects will be assessed</measure>
    <time_frame>After 28 days of medication</time_frame>
    <description>The changes of the volume of liquid on B-mode at different observation points before and after treatment will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The white blood cells of 184 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>assessment of the white blood returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The TCM syndrome scores of 184 subjects will be assessed</measure>
    <time_frame>Change from base line on the 56 days after discontinuation</time_frame>
    <description>assessment of the 70% reduction rate after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The VAS score of 184 subjects will be assessed</measure>
    <time_frame>Change from base line on the 56 days after discontinuation</time_frame>
    <description>assessment of the 70% reduction rate after treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Change from base line on the 21 day of medication and from 28 days on 56 days after the end of</time_frame>
    <description>Observe the incidence of adverse events after medication</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of liver function</measure>
    <time_frame>Change from base line on the 21 day of medication and from 28 days on 56 days after the end of</time_frame>
    <description>To observe whether ALT and AST are within the normal reference range after medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of renal function</measure>
    <time_frame>Change from base line on the 21 day of medication and from 28 days on 56 days after the end of</time_frame>
    <description>To observe whether creatinine and urea nitrogen are within the normal reference range after treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Pelvic Inflammatory Diseases</condition>
  <arm_group>
    <arm_group_label>Qianjin Capsule of Gynaecology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days.
One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotics alone group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days.
One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qianjin Capsule of Gynaecology</intervention_name>
    <description>To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.</description>
    <arm_group_label>Antibiotics alone group</arm_group_label>
    <arm_group_label>Qianjin Capsule of Gynaecology</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Women aged 20-50;

          -  (2) Sexual History ;

          -  (3) According to the diagnostic criteria of pelvic inflammatory diseases: according to
             the Diagnosis and Treatment Criteria of Pelvic Inflammatory Diseases (2014), the
             following specifications are as follows: A. uterine tenderness, or adnexal tenderness,
             or cervical lifting pain; B. axillary body temperature &lt; 38 C. blood routine white
             blood cell count &lt; 1.1 times the upper limit of normal value; D. blood routine
             neutrophil percentage &lt; 90%; All of the above four items are available. Exclusion
             Criteria:

          -  (4)4＜McCormack＜12;

          -  (5)TCM syndrome differentiation for damp-heat stagnation and Qi deficiency syndrome,
             A. lower abdominal pain; B. excessive amount of belt, yellow color, or odor; C.
             fatigue; D. tongue red, greasy fur, or with teeth marks, or blood stasis spots; the
             above four items are all available;

          -  (6)Those who agree to participate in this clinical trial and sign the informed consent
             form.

        Exclusion Criteria:

          -  (1) Pregnant or recent (within 6 months) pregnant women, lactating women ;

          -  (2) To identify the pathogen as Neisseria gonorrhoeae;

          -  (3) Symptoms related to appendicitis, ectopic pregnancy, torsion or rupture of ovarian
             cyst pedicle, gastroenteritis, endometriosis, adenomyosis, trichomonal vaginitis,
             vulvovaginal candidiasis, bacterial vaginosis, etc.;

          -  (4)Those with critical condition or surgical indications, such as fallopian tube and
             ovary abscess, pelvic abscess, diffuse peritonitis, septicemia;

          -  (5)In patients with severe primary diseases such as heart, brain and hematopoietic
             system, ALT of liver function is higher than the upper limit of normal value, and Cr
             of renal function is higher than the upper limit of normal value;

          -  (6)One month before admission, Chinese and Western medicines were used to treat the
             disease, which made it difficult to judge the efficacy of drugs;

          -  (7)Anaphylactic constitution or persons known to be allergic to the medicines and
             their components used in this test ;

          -  (8)Researchers do not consider it appropriate to participate in this clinical trial;

          -  (9)Suspected or true history of alcohol and drug abuse, or other pathological changes
             or conditions that reduce the likelihood of enrollment or complicate enrollment, such
             as frequent changes in the working environment, unstable living environment, etc., are
             liable to lead to lost interviews, according to the judgement of researchers;

          -  (10)Participation in other clinical researchers within 3 months before admission;

          -  (11)Patients with suspected or confirmed quinolone contraindications, central or
             peripheral neuropathy, epilepsy, and depression
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanming Xie, BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanming Xie, BA</last_name>
    <phone>86-13911112416</phone>
    <email>ktzu2018@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kun Ma, Doctor</last_name>
    <phone>86-13521781839</phone>
    <email>wlxing@126.com</email>
  </overall_contact_backup>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Yanming Xie</investigator_full_name>
    <investigator_title>Deputy director</investigator_title>
  </responsible_party>
  <keyword>Qianjin Capsule of Gynaecology</keyword>
  <keyword>efficacy and safety</keyword>
  <keyword>recurrence rate</keyword>
  <keyword>randomized</keyword>
  <keyword>double blind</keyword>
  <keyword>parallel control</keyword>
  <keyword>multi-center clinical study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Inflammatory Disease</mesh_term>
    <mesh_term>Pelvic Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

